MALOBERTI ALESSANDRO

Maloberti, A., Garofani, I., Giannattasio, C. (2025). Reply to: “Uric acid in metabolic syndrome: An innocent bystander or a central player?”. INTERNATIONAL JOURNAL OF CARDIOLOGY, 421(15 February 2025) [10.1016/j.ijcard.2024.132922]. Dettaglio

Maloberti, A., Colombo, V., Daus, F., De Censi, L., Abrignani, M., Temporelli, P., et al. (2025). Two still unanswered questions about uric acid and cardiovascular prevention: Is a specific uric acid cut-off needed? Is hypouricemic treatment able to reduce cardiovascular risk?. NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 35(3(March 2025)) [10.1016/j.numecd.2024.103792]. Dettaglio

Binaghi, G., Abrignani, M., Temporelli, P., Casula, M., Maloberti, A., Riccio, C., et al. (2025). Potassium role in the human body and clinical implications of hyperkalemia. GIORNALE ITALIANO DI CARDIOLOGIA, 26(1), 50-60 [10.1714/4394.43959]. Dettaglio

Tognola, C., Myriam Intravaia, R., Senini, E., Pezzoli, S., Riccio, A., Gualini, E., et al. (2025). Secondary prevention and extreme cardiovascular risk evaluation (SEVERE-0): Prevalence of extreme cardiovascular risk in cardiological rehabilitation patients and its impact on functional improvement. NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 35(2 (February 2025)) [10.1016/j.numecd.2024.08.006]. Dettaglio

Tognola, C., Ruzzenenti, G., Maloberti, A., Varrenti, M., Mazzone, P., Giannattasio, C., et al. (2025). Anderson–Fabry Disease: An Overview of Current Diagnosis, Arrhythmic Risk Stratification, and Therapeutic Strategies. DIAGNOSTICS, 15(2) [10.3390/diagnostics15020139]. Dettaglio